"Mechlorethamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
| Descriptor ID |
D008466
|
| MeSH Number(s) |
D02.455.526.728.650.529
|
| Concept/Terms |
Mechlorethamine- Mechlorethamine
- Chlormethine
- Bis(2-chloroethyl)methylamine
- Mustine
- Nitrogen Mustard
- Chlorethazine
- Methylchlorethamine
Mechlorethamine Hydrochloride N-Oxide- Mechlorethamine Hydrochloride N-Oxide
- Hydrochloride N-Oxide, Mechlorethamine
- Mechlorethamine Hydrochloride N Oxide
- N-Oxide, Mechlorethamine Hydrochloride
Mechlorethamine N-Oxide- Mechlorethamine N-Oxide
- Mechlorethamine N Oxide
- Nitrogen Mustard N-Oxide
- N-Oxide, Nitrogen Mustard
- Nitrogen Mustard N Oxide
|
Below are MeSH descriptors whose meaning is more general than "Mechlorethamine".
Below are MeSH descriptors whose meaning is more specific than "Mechlorethamine".
This graph shows the total number of publications written about "Mechlorethamine" by people in this website by year, and whether "Mechlorethamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechlorethamine" by people in Profiles.
-
Concomitant mycosis fungoides and vitiligo: how mycosis fungoides may contribute to melanocyte destruction. Dermatology. 2015; 230(2):143-9.
-
Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):591-7.
-
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan; 149(1):25-32.
-
Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc. 2011 Dec 07; 133(48):19278-81.
-
Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. Int J Dermatol. 2012 Oct; 51(10):1231-3.
-
Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature. J Pediatr Hematol Oncol. 2008 Dec; 30(12):976-80.
-
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007 May 01; 67(9):4459-66.
-
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park). 2007 Feb; 21(2 Suppl 1):33-40.
-
Topical nitrogen mustard for the treatment of granulomatous slack skin. Am J Clin Dermatol. 2007; 8(1):51-4.
-
POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006 Jun; 28(6):362-8.